靶向治疗在白癜风中的研究进展OA北大核心CSTPCD

Vitiligo is a common acquired depigmentation disorder characterized by the loss of melanocytes in the skin,hair,and mucous membranes.Its characteristics of difficulty in re-pigmentation and easy recurrence are great challenges for vitiligo treat-ment.At present,vitiligo has been clearly classified as an autoimmune disease with a complex pathogenesis involving genetic and envi-ronmental factors,oxidative stress and autoimmune responses that synergistically promote the loss of melanocytes.With the in-depth understanding of the pathogenesis of vitiligo,a large number of clinical trials have been carried out for targeted therapy of key small molecules,cell subsets,and immune-related signaling pathways in vitiligo.Targeted therapy will become the mainstream in the treat-ment of vitiligo in the future.Research progress of targeted therapy for tissue resident memory T cells(TRM)pathway,JAK-STAT pathway,and WNT/β-catenin pathway in vitiligo.